Drug Trial Radar · NCT07861542
Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
669
Actual
Start
Oct 1, 2026
Primary completion
Nov 26, 2026
Study completion Jan 27, 2027
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Oct 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and immunogenicity of a single dose of Sanofi's Omicron subvariant-based Nuvaxovid in participants ≥ 65 years of age and participants 12 through 64 years of age who have at least one underlying condition that puts them at increased risk for severe outcomes of COVID-19 and who have been previously vaccinated with a COVID-19 vaccine ≥ 90 days prior to study vaccination. Study details include: * The study duration will be approximately 3 months per participant. * Study intervention will be administered via a single intramuscular (IM) injection into the deltoid muscle on Day 1. * The visit frequency will be Day 1, Day 9 telephone call, Day 29, and Day 91 telephone call (3-month safety follow-up).
Conditions
- COVID-19
Interventions
Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Matrix-MBiological
Pharmaceutical form: Sterile suspension for injection Route of administration: Intramuscular injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Geometric Mean Fold Rise (GMFR) in pseudovirus neutralizing antibody titers (ID50) against the Omicron subvariant included in the vaccine formulation from pre-vaccination to 28 days post-vaccination.Time frame: Day 1 (pre-vaccination) and Day 29 (28 days after vaccination)
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Site #: 8400005
Fair Oaks, California
Site #: 8400002
Doral, Florida
Site #: 8400008
Atlanta, Georgia
Site #: 8400015
Decatur, Georgia
Site #: 8400011
Melrose Park, Illinois
Site #: 8400019
Sioux City, Iowa
Site #: 8400009
Lenexa, Kansas
Site #: 8400001
Lafayette, Louisiana
Site #: 8400003
New Orleans, Louisiana
Site #: 8400024
Rockville, Maryland
Site #: 8400012
Southfield, Michigan
Site #: 8400023
Grand Island, Nebraska
Site #: 8400004
Omaha, Nebraska
Site #: 8400021
Omaha, Nebraska
Site #: 8400016
Cincinnati, Ohio
Site #: 8400007
Philadelphia, Pennsylvania
Site #: 8400018
Austin, Texas
Site #: 8400017
Frisco, Texas
Site #: 8400014
Houston, Texas
Site #: 8400013
Richmond, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.